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1084he safety and efficacy of intravenous low-molecular-weight
eparin (LMWH) anticoagulation in patients undergoing
ither emergent or elective percutaneous coronary interven-
ion (PCI) has previously been demonstrated in a number of
rials (1–8). The largest of these trials in elective PCI was
he STEEPLE (SafeTy and Efficacy of Enoxaparin in PCI
atients, an internationaL randomized Evaluation) trial,
hich was a prospective, open-label, parallel-group study
See page 1092
valuating intravenous enoxaparin (0.50 mg/kg or 0.75
g/kg) and unfractionated heparin (UFH) in patients with
table coronary artery disease (7). The study found that
noxaparin was associated with reduced bleeding rates,
compared with UFH. Notably,
the beneficial effect of enoxapa-
rin was primarily driven by a
significant 57% reduction in
noncoronary artery bypass graft-
related major bleeding in the
first 48 h compared with UFH
(7). Although the STEEPLE
study was not powered to make
definitive conclusions regarding
efficacy, a subsequent meta-
analysis of 13 randomized stud-
ies, which was sufficiently pow-
ered, reported similar efficacy
between UFH and LMWH (6).
However, none of 13 pub-
lished randomized studies has
examined the long-term out-
comes of PCI in patients receiv-
ing intravenous LMWH or
UFH. In this study, we present
data from a 1-year follow-up of
the STEEPLE trial, during
which we evaluated patient out-
omes and identified factors associated with long-term
ortality.
ethods
etween January 2004 and December 2004, a total of 3,528
atients were enrolled into the STEEPLE trial. Briefly,
,070 were randomly assigned to receive enoxaparin 0.50
g/kg intravenously, 1,228 to enoxaparin 0.75 mg/kg
ntravenously, and 1,230 to activated clotting time (ACT)-
djusted UFH (7). Randomization was stratified according
o the medical center and planned use of glycoprotein
Ib/IIIa inhibitors. Regardless of weight or renal function,
atients were eligible for the study if they were age 17
bbreviations
nd Acronyms
CS  acute coronary
yndromes
CT  activated clotting
ime
I  confidence interval
K  creatine kinase
K-MB  creatine kinase-
yocardial/brain mass
R  hazard ratio
MWH  low-molecular-
eight heparin
I  myocardial infarction
CI  percutaneous
oronary intervention
FH  unfractionated
eparin
LNR  upper limit of the
ormal range
TVR  urgent target vessel
evascularizationears, were scheduled to undergo elective PCI with a gemoral approach, did not meet any of the exclusion criteria,
nd gave informed consent. The exclusion criteria included
ecent thrombolysis, a planned staged procedure, an in-
reased risk of bleeding, treatment with a parenteral anti-
hrombotic agent before PCI, or a known hypersensitivity to
he drugs used in the study. The study complied with the
eclaration of Helsinki, and locally appointed ethics com-
ittees approved the research protocol.
A follow-up analysis of clinical outcomes in patients
nrolled in the STEEPLE trial, which was not part of the
riginal study protocol, was initiated in December 2005—
year after the closure of the primary study. From the
riginal 124 centers, 25 did not participate in this analysis
nd 892 patients were lost to follow-up beyond day 30.
easons for the loss of follow-up data were: no internal
eview board approval (n  154); contractual issues (n 
35); lengthy administrative procedures (n  115); unwill-
ngness to participate (n  113); other reasons (n  75).
reatment protocol. Patients were treated with aspirin (75
o 500 mg/day) and thienopyridines according to local
ractice. Before PCI, 46% of patients had received long-
erm treatment with thienopyridine. On the day of PCI,
pproximately 40% of patients in each treatment arm had
eceived a glycoprotein IIb/IIIa inhibitor and 94% a thieno-
yridine. Patients in the control arm, who were not receiv-
ng concurrent glycoprotein IIb/IIIa inhibitors, were given
n initial intravenous bolus of 70 to 100 IU/kg UFH to
chieve a target ACT of 300 to 350 s. Patients who received
oncurrent glycoprotein IIb/IIIa inhibitors were given an
nitial bolus of 50 to 70 IU/kg of UFH to achieve a target
CT of 200 to 300 s. Additional boluses of UFH (before
he start of PCI and during the procedure) were given to
6.5% of patients when ACT measurements dropped below
he recommended range. Patients receiving enoxaparin were
ot routinely monitored for anticoagulation levels, and
either dose regimen was adjusted according to the con-
omitant use of glycoprotein IIb/IIIa inhibitors.
In the original study, a nonsignificant increase in mortal-
ty up to 30 days after index PCI was observed in patients
eceiving 0.50 mg/kg enoxaparin, compared with UFH,
hich resulted in early closure of the low-dose enoxaparin
rm (7).
nd points at 1 year. The primary end point for this analysis
as all-cause mortality at 1 year. Data on all-cause mortality
t 1 year were gathered by telephone or by visiting partici-
ating sites; no information on cause of mortality or other
dverse events was collected.
tatistical analyses. All-cause mortality at 1 year was ana-
yzed using a Cox proportional hazard model. All patients
nrolled in the initial STEEPLE trial, whatever the dura-
ion of follow-up, were included in this model. Each
noxaparin dose was compared with UFH separately. The
imes adjustment for multiplicity was applied to ensure a
lobal type 1 error rate of 0.05: if both p values were 0.05 or
l
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1085ess, both were considered as statistically significant; if the
ighest p value was0.05, the other p value had to be 0.025
r less to be considered statistically significant. Kaplan-
eier curves were used to present the calculated probability
f mortality over time.
Univariate and stepwise multivariate (significance level
or entering variables  0.25, significance levels for retain-
ng variables  0.05) Cox proportional hazard models were
sed to identify risk factors associated with all-cause mor-
ality at 1 year. The following variables were included in
hese analyses: subjects’ characteristics (age, sex, obesity,
iabetes, measured hypertension, smoking habits, hyper-
holesterolemia, renal insufficiency [creatinine clearance
60 ml/min], peripheral arterial disease, family history of
oronary heart disease, unstable angina or myocardial in-
arction [MI] within the previous 7 days, low hemoglobin at
ntry [10 g/dl and 11 g/dl for female and male patients,
espectively]); PCI characteristics (number of diseased ar-
eries, number of dilated arteries, maximum sheath size, use
f closure device, time from end of PCI to sheath removal,
rug-eluting stent, Thrombolysis In Myocardial Infarction
ow grade [pre-procedure]); previous medication within 1
eek before enrollment (beta-blocker, calcium-channel
locker, angiotensin-converting enzyme inhibitor, angio-
ensin receptor blocker, statin, warfarin, or other vitamin K
ntagonists); concomitant medication (glycoprotein IIb/IIIa
nhibitor, thrombolytic during PCI, dose of aspirin on the
ay of PCI, clopidogrel loading dose, and glycoprotein
Ib/IIIa inhibitor and clopidogrel dose on the day of PCI);
nticoagulant crossover during the index hospitalization;
Table 1. Baseline Characteristics of Patients in 1-Ye
Characteristics
Enoxaparin 0.50 m
(n  792)
Mean age, yrs 63.7 10.3
Age 75 yrs 138 (17.4)
Men 590 (74.5)
Mean weight, kg 83.7 16.3
Body mass index 30 kg/m2 295 (37.5)
Creatinine clearance, ml/min
30–60 141 (18.1)
30 10 (1.3)
Diabetes 229 (28.9)
Prior MI
48 h to 7 days 12 (1.5)
48 h 2 (0.3)
Prior unstable angina
48 h to 7 days 57 (7.2)
48 h 37 (4.7)
Prior PCI 274 (34.6)
Prior CABG 113 (14.3)
Values expressed as mean SD or n (%).
CABG coronary artery bypass graft; MImyocardial infarction; Pountry; nonfatal MI or urgent target vessel revasculariza- rion (UTVR), considered as a time-dependent covariate;
reatine kinase (CK) and creatine kinase-myocardial/brain
ass (CK-MB); and major bleeding up to 48 h.
Nonfatal MI was defined by a new Q-wave in 2 or more
eads, or a total CK level or CK-MB fraction that was3
he upper limit of the normal range (ULNR) during
ospitalization for the index PCI, or 2 ULNR after
ischarge. Nonfatal MI was defined by a new Q-wave in 2
r more leads, or a total CK level or CK-MB fraction that
as 3  ULNR during hospitalization for the index PCI,
r 2 ULNR after discharge. The definition for major
leeding and the associated time point were used as reported
reviously (7).
esults
n total, 3,528 patients were randomized to receive either
.50-mg/kg or 0.75-mg/kg enoxaparin, or UFH. Of these
atients, 1-year follow-up data were available for 2,636
atients. The baseline characteristics of patients included in
his study were well balanced between treatment groups
Table 1). Importantly, these baseline characteristics were
imilar in patients evaluated in the 1-year follow-up com-
ared with those who were not (Table 1). The only
ignificant differences in patient populations included in this
tudy and those lost to follow-up were the number of
atients with diabetes in the UFH treatment arm and the
umber of patients with moderate renal impairment in the
.75-mg/kg enoxaparin arm.
-year results by treatment arm. One-month results were
low-Up Subanalysis
Enoxaparin 0.75 mg/kg
(n  915)
UFH
(n  929)
63.8 10.1 63.5 10.2
134 (14.6) 143 (15.4)
685 (74.9) 685 (73.7)
83.8 16.0 83.1 15.8
308 (34.1) 319 (34.6)
175 (19.5) 161 (17.7)
6 (0.7) 17 (1.9)
257 (28.1) 269 (29.0)
15 (1.6) 17 (1.8)
6 (0.7) 3 (0.3)
60 (6.6) 64 (6.9)
51 (5.6) 39 (4.2)
329 (36.0) 358 (38.5)
125 (13.7) 142 (15.3)
rcutaneous coronary intervention; UFH unfractionated heparin.ar Fol
g/kgeported previously (7). There were no significant differ-
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1086nces between the treatment arms for all-cause mortality
valuated between 1 month and 1 year after index PCI:
.4% for enoxaparin 0.50 mg/kg (p  0.86 vs. UFH); 2.0%
or enoxaparin 0.75 mg/kg (p  0.45 vs. UFH); and 1.5%
or UFH (Fig. 1A). Subsequently, we observed comparable
ates of all-cause mortality at 1 year in the 3 treatment
Figure 1. Kaplan-Meier Survival Curves for All-Cause Mortality According to
Kaplan-Meier survival curves for enoxaparin (Enox) 0.50 mg/kg and 0.75 mg/kg
sis of all-cause mortality starting at day 30 post-randomization; and (B) all-cauroups: 2.3% for enoxaparin 0.50 mg/kg (hazard ratio cHR]: 1.3, 95% confidence interval [CI]: 0.70 to 2.41; p 
.41); 2.2% for enoxaparin 0.75 mg/kg (HR: 1.12, 95% CI:
.60 to 2.08; p  0.72); and 1.9% for UFH (Fig. 1B).
redictors of mortality at 1 year. After univariate analysis,
ortality was significantly higher in patients who had an
schemic event (nonfatal MI and/or UTVR) up to day 30,
y Treatment
unfractionated heparin (UFH) treatment groups showing (A) landmark analy-
rtality from randomization to 1 year.Stud
, andompared with those who did not (Fig. 2A). Nonfatal MI
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1087p to 30 days after PCI was independently associated
ith mortality when this event was considered separately
rom UTVR (5.7% vs. 2.0%, respectively; p  0.008). In
ddition, a strong relationship was observed between
ost-procedural CK or CK-MB fraction release and
Figure 2. All-Cause Mortality Rates According to the Occurrence of Initial
All-cause mortality rates at 1 year in patients who did, or did not experience t
revascularization (UTVR); (B) increased creatine kinase (CK) levels or creatine ki
ULNR  upper limit of the normal range.-year mortality. Rates of mortality were significantly tncreased in patients with raised levels of total CK or
K-MB (Fig. 2B). This relationship remained strong
nd significant regardless of the threshold for significant
K increase used. Mortality was significantly higher in
atients who experienced major bleeding compared with
ic or Bleeding Complications
owing events: (A) nonfatal myocardial infarction (MI) or urgent target vessel
yocardial/brain mass (CK-MB) fraction release; and (C) major bleeding.Ischem
he foll
nase-mhose who did not (Fig. 2C).
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1088Multivariate analysis indicated that ischemic events (MI
r UTVR) in the first 30 days after PCI, and major bleeding
ithin 48 h after index PCI were the 2 strongest indepen-
ent predictors for all-cause mortality at 1 year, with similar
Rs of 3.5 and 3.0, respectively (Fig. 3). When MI was
onsidered independently of UTVR, an odds ratio of 3.29
95% CI: 1.53 to 7.05; p  0.002) was obtained. The
umber of diseased coronary arteries and the presence of
eripheral arterial disease were also significant predictors of
ortality (Fig. 3). The presence of diabetes and baseline
enal insufficiency as well as age 75 years were also
ssociated with increased 1-year mortality. Interestingly, the
nvestigators’ choice of using100 mg of aspirin at the time
f PCI was the only variable associated with improved
ortality.
iscussion
his update of the STEEPLE trial showed that all-cause
ortality at 1 year was low in patients undergoing elective
CI. Mortality rates were similar in enoxaparin and UFH
reatment groups, although this study was not powered to
raw final conclusions on mortality. Mortality rates in-
reased sharply in patients with a periprocedural ischemic or
leeding event.
These data are consistent with studies performed in the
ontext of patients with acute coronary syndromes (ACS);
noxaparin and UFH are associated with similar efficacy (in
Figure 3. Risk Factor Analysis for All-Cause Mortality at 1 Year
ASA  aspirin; CI  conﬁdence interval; HR  hazard ratio; PCI  percutaneoerms of the reduction of ischemic events) and long-term tortality (6,8,9). Although the original analysis showed a
onsignificant trend towards increased short-term mortality
ith enoxaparin 0.50 mg/kg over the first 30 days after
ndex PCI, resulting in enrollment in this arm being
topped prematurely (lower mortality rates were observed in
atients receiving enoxaparin 0.75 mg/kg [7]), this trend
as reversed in mortality rates from 1 month to 1 year, with
lower mortality rate being observed in the 0.50-mg/kg
noxaparin arm (a higher mortality rate was observed in the
.75-mg/kg arm).
The observed trends in mortality across treatment groups
eflect variations in rare events in a low-risk population
ecruited in a trial not powered to assess mortality, with
hance being the most likely explanation for these varia-
ions. Furthermore, reductions in both in-hospital mortality
ombined with nonfatal reinfarction, and in-hospital mor-
ality alone, have been observed in ST-segment elevation
I patients receiving enoxaparin (10,11), and more recently
n a trial using the same dose of intravenous enoxaparin
0.50 mg/kg) in primary PCI (12).
Major bleeding is a hard clinical end point associated
ith increased long-term mortality. Its importance is un-
erlined in the guidelines for the management of patients
ith non–ST-segment elevation ACS, which recommend
he risk stratification of patients according to bleeding (13),
nd in a recent subanalysis of the ACUITY (Acute Cath-
terization and Urgent Intervention Triage strategy) ACS
onary intervention; other abbreviations as in Figure 2.rial, which reported a significant association between major
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1089leeding and 1-year mortality (14). The STEEPLE trial
emonstrated that in patients undergoing elective PCI,
ewer major bleeding complications occurred at 30 days with
ntravenous enoxaparin than with UFH. Periprocedural
ajor bleeding is increasingly being recognized as a sub-
tantial cause of short-term morbidity and mortality in
lective PCI (15–17). The association between major bleed-
ng and morbidity or mortality has been reported to be
emporal (with the greatest risk during the first 30 days, and
arkedly reduced risk if patients survive at least 30 days
fter a major bleed), and linked to severity (with a higher
isk of death in those with more severe degrees of bleeding)
16,17). Our data suggest that this relationship between
ajor bleeding and mortality extends at least up to 1 year
fter PCI.
One of several explanations for the relationship between
ajor bleeding and 1-year mortality is that major bleeding
ight lead physicians to discontinue effective antithrom-
otic drugs such as aspirin, clopidogrel, heparin, LMWH,
nd warfarin, which in turn could increase the risk of MI,
troke, and cardiovascular death. These data suggest signif-
cant clinical benefits can be achieved by using novel
trategies based on the use of new antithrombotic agents
7,12,18,19), and/or of new techniques (such as radial
pproach for PCI) capable of reducing major bleeding
20–22).
Our analysis also shows that even with the use of
rug-eluting stents, thienopyridines, and glycoprotein
Ib/IIIa inhibitors, ischemic events as measured in the
rst 30 days after PCI, remain the most important
redictor of mortality at 1 year. Periprocedural CK
elease was also strongly associated with 1-year mortality,
egardless of the cutoff value defining increased CK or
K-MB release. These findings confirm observations
rom previous studies, which reported periprocedural
yonecrosis as a predictor of major adverse cardiac events
nd death (23–25) and support the new “universal defi-
ition of MI” (26).
Consistent with findings from previous studies, we iden-
ified multivessel coronary disease, peripheral arterial dis-
ase, diabetes mellitus, and renal disease, as well as advanc-
ng age (75 years) as major risk factors for poor clinical
utcomes (27–29). These factors are markers of the extent
f the atherothrombotic process exposing the patient to
urther ischemic events and death. Questions remain re-
arding the safety and efficacy of PCI for patients presenting
ith several of these independent markers of mortality,
ndicating chronic, systemic, and diffuse disease in different
ascular beds. Tailoring the intensity of antithrombotic
herapy acutely, and after discharge as secondary prevention
o individual risk, could become an important goal for the
uture (29,30).
Although all study sites participating in the STEEPLE trial
ere contacted, 25 centers did not participate in this analysis, Snd overall 892 patients were lost to follow-up. Despite the
imitations of this incomplete follow-up, there was no evidence
or selection bias as the baseline characteristics of patients
ncluded in this subanalysis matched well with both the overall
TEEPLE study population and those who were lost to
ollow-up. A key limitation of this study was the loss of
tatistical power resulting from the incompleteness of
ollow-up data availability. Full data on adverse clinical events,
uch as cardiac death, MI, and repeat revascularization up to
year, were not collected during this study.
onclusions
n summary, the data from the STEEPLE study show that
-year mortality rates were low and comparable between
atients receiving enoxaparin (0.50 mg/kg or 0.75 mg/kg)
nd UFH during elective PCI. Periprocedural major bleed-
ng and ischemic events were the most serious independent
redictors of death at 1 year. Reduction in major bleeding
ver the first 48 h after PCI and prevention of CK release
re important to improve the long-term survival of patients
ndergoing PCI.
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